July 18, 2019
Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
Learn more >>

June 25, 2019
Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries
Learn more >>

June 06, 2019
Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, Named Finalist for The 2019 EY Entrepreneur Of The Year® Award in New Jersey
Learn more >>

June 04, 2019
Rafael Pharmaceuticals to Present at the 2019 Jefferies Global Healthcare Conference
Learn more >>

May 16, 2019
Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala
Learn more >>

May 13, 2019
Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations
Learn more >>

February 07, 2019
CPI-613® (devimistat) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”
Learn more >>

January 17, 2019
Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium
Learn more >>

January 10, 2019
EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (devimistat) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn more >>

January 10, 2019
EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (devimistat) for Treatment of Metastatic Pancreatic Cancer
Learn more >>

January 09, 2019
Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613® in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Learn more >>

January 09, 2019
Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613® for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
Learn more >>

January 07, 2019
Rafael Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Learn more >>